Sharing Wilsons' updated report on LLL below.
Regarding their Target Price, it's important to note the following:
- Project NPV is valued at A$5.24/share and LLL's effective project interest of 36% ownership (after Malian Government's 10% free-carry) equates to NPV of A$2.01/share.
- Wilsons states that if LLL chose to liquidate their remaining 35.5% economic interest in Goulamina at the same valuation as their recently sold 5% stake in the asset (sold for US$65m to JV partner Ganfeng), this would still result in a company valuation of ~A65cps (~30% above the suspended share price).
- Wilsons target price of 45cps is only based on a conservative 30% discount to the ‘liquidate scenario’ valuation (point 2), which will be rerated / re-linked to their assessment of project NPV (A$2.01/share) once production commences later this year and when there is more certainty over the regulatory and ownership outlook (coming shortly).
@fooca@Red Baron@8horse@manny100@dazaliam@MM0@franky1@zzya1979
- Forums
- ASX - By Stock
- LLL
- General Discussion
General Discussion, page-9473
Featured News
Add LLL (ASX) to my watchlist
(20min delay)
|
|||||
Last
50.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $605.4M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
LLL (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online